BCDA BioCardia

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.

To access the call today:

Participants can register for the conference by navigating to . Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730 and ask to be connected to the BioCardia call. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: .

A webcast replay of the call will be available approximately one hour after the end of the call at the above links. To access the replay internationally, please use the link . A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156.



Media Contact:
Miranda Peto, Marketing / Investor Relations
Email:  
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email:  
Phone: 650-226-0120
EN
31/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE

BioCardia Submits Request for Clinical Data Review Meeting with Japan ...

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure SUNNYVALE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it submitted its CardiAMP autologous cell therapy investigational heart failure treatment for clinical consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This milestone marks a significant step toward pote...

 PRESS RELEASE

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAM...

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial. “The CardiAMP HF cell therapy trials are important for patients with ischemic heart failure in ne...

 PRESS RELEASE

BioCardia Announces New United States Patent for Helix Biotherapeutic ...

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and Trans-endocardial Delivery Catheter”. US Patent No. 12,311,127 describes the Company’s minimally invasive interventional catheter systems to deliver biologic therapies to target sites in the he...

 PRESS RELEASE

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare...

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will sh...

 PRESS RELEASE

BioCardia Reports First Quarter 2025 Business Highlights and Financial...

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) --  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s forma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch